Effects of altitude and recombinant human erythropoietin on iron metabolism: a randomized controlled trial

Publikation: Bidrag til tidsskriftTidsskriftartikelfagfællebedømt

Standard

Effects of altitude and recombinant human erythropoietin on iron metabolism: a randomized controlled trial. / Breenfeldt Andersen, Andreas; Bonne, Thomas Christian; Bejder, Jacob; Jung, Grace; Ganz, Tomas; Nemeth, Elizabeta; Olsen, Niels Vidiendal; Rodriguez Huertas, Jesus; Nordsborg, Nikolai Baastrup.

I: American Journal of Physiology: Regulatory, Integrative and Comparative Physiology, Bind 321, Nr. 2, 2021, s. R152-R161.

Publikation: Bidrag til tidsskriftTidsskriftartikelfagfællebedømt

Harvard

Breenfeldt Andersen, A, Bonne, TC, Bejder, J, Jung, G, Ganz, T, Nemeth, E, Olsen, NV, Rodriguez Huertas, J & Nordsborg, NB 2021, 'Effects of altitude and recombinant human erythropoietin on iron metabolism: a randomized controlled trial', American Journal of Physiology: Regulatory, Integrative and Comparative Physiology, bind 321, nr. 2, s. R152-R161. https://doi.org/10.1152/ajpregu.00070.2021

APA

Breenfeldt Andersen, A., Bonne, T. C., Bejder, J., Jung, G., Ganz, T., Nemeth, E., Olsen, N. V., Rodriguez Huertas, J., & Nordsborg, N. B. (2021). Effects of altitude and recombinant human erythropoietin on iron metabolism: a randomized controlled trial. American Journal of Physiology: Regulatory, Integrative and Comparative Physiology, 321(2), R152-R161. https://doi.org/10.1152/ajpregu.00070.2021

Vancouver

Breenfeldt Andersen A, Bonne TC, Bejder J, Jung G, Ganz T, Nemeth E o.a. Effects of altitude and recombinant human erythropoietin on iron metabolism: a randomized controlled trial. American Journal of Physiology: Regulatory, Integrative and Comparative Physiology. 2021;321(2):R152-R161. https://doi.org/10.1152/ajpregu.00070.2021

Author

Breenfeldt Andersen, Andreas ; Bonne, Thomas Christian ; Bejder, Jacob ; Jung, Grace ; Ganz, Tomas ; Nemeth, Elizabeta ; Olsen, Niels Vidiendal ; Rodriguez Huertas, Jesus ; Nordsborg, Nikolai Baastrup. / Effects of altitude and recombinant human erythropoietin on iron metabolism: a randomized controlled trial. I: American Journal of Physiology: Regulatory, Integrative and Comparative Physiology. 2021 ; Bind 321, Nr. 2. s. R152-R161.

Bibtex

@article{f96acfba13934af69f9a8d86e14813d5,
title = "Effects of altitude and recombinant human erythropoietin on iron metabolism: a randomized controlled trial",
abstract = "Current markers of iron deficiency (ID) such as ferritin and hemoglobin have shortcomings, and hepcidin and erythroferrone (ERFE) could be of clinical relevance in relation to early assessment of ID. Here, we evaluate whether exposure to altitude-induced hypoxia (2,320 m) alone, or in combination with recombinant human erythropoietin (rHuEPO) treatment, affects hepcidin and ERFE levels before alterations in routine ID biomarkers and stress erythropoiesis manifest. Two interventions were completed, each comprising a 4-wk baseline, a 4-wk intervention at either sea level or altitude, and a 4-wk follow-up. Participants (n=39) were randomly assigned to 20 IU·kg body wt-1 rHuEPO or placebo injections every second day for 3 wk during the two intervention periods. Venous blood was collected weekly. Altitude increased ERFE (P ≤ 0.001) with no changes in hepcidin or routine iron biomarkers, making ERFE of clinical relevance as an early marker of moderate hypoxia. rHuEPO treatment at sea level induced a similar pattern of changes in ERFE (P < 0.05) and hepcidin levels (P < 0.05), demonstrating the impact of accelerated erythropoiesis and not of other hypoxia-induced mechanisms. Compared to altitude alone, concurrent rHuEPO treatment and altitude exposure induced additive changes in hepcidin (P < 0.05) and ERFE (P ≤ 0.001) parallel with increases in hematocrit (P < 0.001), demonstrating a relevant range of both hepcidin and ERFE. A poor but significant correlation between hepcidin and ERFE was found (R2 = 0.13, P < 0.001). The findings demonstrate that hepcidin and ERFE are more rapid biomarkers of changes in iron demands than routine iron markers. Finally, ERFE and hepcidin may be sensitive markers in an anti-doping context.Clinical trial registration: Clinical trials identifier, NCT04227665",
keywords = "Faculty of Science, Hepcidin, Erythroferrone, Altitude, Anti-doping, Biomarker",
author = "{Breenfeldt Andersen}, Andreas and Bonne, {Thomas Christian} and Jacob Bejder and Grace Jung and Tomas Ganz and Elizabeta Nemeth and Olsen, {Niels Vidiendal} and {Rodriguez Huertas}, Jesus and Nordsborg, {Nikolai Baastrup}",
note = "CURIS 2021 NEXS 247",
year = "2021",
doi = "10.1152/ajpregu.00070.2021",
language = "English",
volume = "321",
pages = "R152--R161",
journal = "American Journal of Physiology",
issn = "0363-6119",
publisher = "American Physiological Society",
number = "2",

}

RIS

TY - JOUR

T1 - Effects of altitude and recombinant human erythropoietin on iron metabolism: a randomized controlled trial

AU - Breenfeldt Andersen, Andreas

AU - Bonne, Thomas Christian

AU - Bejder, Jacob

AU - Jung, Grace

AU - Ganz, Tomas

AU - Nemeth, Elizabeta

AU - Olsen, Niels Vidiendal

AU - Rodriguez Huertas, Jesus

AU - Nordsborg, Nikolai Baastrup

N1 - CURIS 2021 NEXS 247

PY - 2021

Y1 - 2021

N2 - Current markers of iron deficiency (ID) such as ferritin and hemoglobin have shortcomings, and hepcidin and erythroferrone (ERFE) could be of clinical relevance in relation to early assessment of ID. Here, we evaluate whether exposure to altitude-induced hypoxia (2,320 m) alone, or in combination with recombinant human erythropoietin (rHuEPO) treatment, affects hepcidin and ERFE levels before alterations in routine ID biomarkers and stress erythropoiesis manifest. Two interventions were completed, each comprising a 4-wk baseline, a 4-wk intervention at either sea level or altitude, and a 4-wk follow-up. Participants (n=39) were randomly assigned to 20 IU·kg body wt-1 rHuEPO or placebo injections every second day for 3 wk during the two intervention periods. Venous blood was collected weekly. Altitude increased ERFE (P ≤ 0.001) with no changes in hepcidin or routine iron biomarkers, making ERFE of clinical relevance as an early marker of moderate hypoxia. rHuEPO treatment at sea level induced a similar pattern of changes in ERFE (P < 0.05) and hepcidin levels (P < 0.05), demonstrating the impact of accelerated erythropoiesis and not of other hypoxia-induced mechanisms. Compared to altitude alone, concurrent rHuEPO treatment and altitude exposure induced additive changes in hepcidin (P < 0.05) and ERFE (P ≤ 0.001) parallel with increases in hematocrit (P < 0.001), demonstrating a relevant range of both hepcidin and ERFE. A poor but significant correlation between hepcidin and ERFE was found (R2 = 0.13, P < 0.001). The findings demonstrate that hepcidin and ERFE are more rapid biomarkers of changes in iron demands than routine iron markers. Finally, ERFE and hepcidin may be sensitive markers in an anti-doping context.Clinical trial registration: Clinical trials identifier, NCT04227665

AB - Current markers of iron deficiency (ID) such as ferritin and hemoglobin have shortcomings, and hepcidin and erythroferrone (ERFE) could be of clinical relevance in relation to early assessment of ID. Here, we evaluate whether exposure to altitude-induced hypoxia (2,320 m) alone, or in combination with recombinant human erythropoietin (rHuEPO) treatment, affects hepcidin and ERFE levels before alterations in routine ID biomarkers and stress erythropoiesis manifest. Two interventions were completed, each comprising a 4-wk baseline, a 4-wk intervention at either sea level or altitude, and a 4-wk follow-up. Participants (n=39) were randomly assigned to 20 IU·kg body wt-1 rHuEPO or placebo injections every second day for 3 wk during the two intervention periods. Venous blood was collected weekly. Altitude increased ERFE (P ≤ 0.001) with no changes in hepcidin or routine iron biomarkers, making ERFE of clinical relevance as an early marker of moderate hypoxia. rHuEPO treatment at sea level induced a similar pattern of changes in ERFE (P < 0.05) and hepcidin levels (P < 0.05), demonstrating the impact of accelerated erythropoiesis and not of other hypoxia-induced mechanisms. Compared to altitude alone, concurrent rHuEPO treatment and altitude exposure induced additive changes in hepcidin (P < 0.05) and ERFE (P ≤ 0.001) parallel with increases in hematocrit (P < 0.001), demonstrating a relevant range of both hepcidin and ERFE. A poor but significant correlation between hepcidin and ERFE was found (R2 = 0.13, P < 0.001). The findings demonstrate that hepcidin and ERFE are more rapid biomarkers of changes in iron demands than routine iron markers. Finally, ERFE and hepcidin may be sensitive markers in an anti-doping context.Clinical trial registration: Clinical trials identifier, NCT04227665

KW - Faculty of Science

KW - Hepcidin

KW - Erythroferrone

KW - Altitude

KW - Anti-doping

KW - Biomarker

U2 - 10.1152/ajpregu.00070.2021

DO - 10.1152/ajpregu.00070.2021

M3 - Journal article

C2 - 34160288

VL - 321

SP - R152-R161

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 0363-6119

IS - 2

ER -

ID: 272724257